- Drugs
- Wednesday, 09 Aug 2023
Homeopathy Market is expected to reach US$ 18,069.91 million by 2030
Plants Segment to Account for Largest Share in Homeopathy Market During 2022–2030
According to our latest study on “Homeopathy Market Forecast to 2030 – COVID-19 Impact and Analysis – by Source, Type, Application, Distribution Channel, and Country. The global homeopathy market is expected to reach US$ 18,069.91 million by 2030 from US$ 6,016.14 million in 2022. The market is estimated to grow with a CAGR of 14.7% from 2022 to 2030. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Homeopathy Market, by Region, 2022 (%)
To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00007419 Source: The Insight Partners Analysis
Healthcare Expenditure and Reimbursement Boosts Market Growth
Homeopathy has been introduced into national healthcare systems in many Asian and European countries, and it is thus often protected by national health insurance. However, there are significant variations in the degree to which homeopathy is reimbursed across European countries. In India, homeopathy is well represented in public health, being a close second among the AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy) services. Homeopathy wellness centres comprise 31% of the total for AYUSH. Seven out of 10 diseases recognised as a national health burden are in the category of most commonly reported diseases at the homeopathy wellness centres. Academic homeopathy institutes comprise 35.8% of AYUSH colleges, the total student intakes of which are 13,658 and 32,256 respectively. Homeopathy practitioners are 37% of the AYUSH total. Homeopathy units comprise 1/19th of the number of allopathy units, yet the annual patient footfall in the former is 1/5th of the latter. Homeopathy services, wherever available, are being used fully and thus sharing the patient load in the government-run wellness centres. There is the potential for more homeopathic practitioners to contribute importantly to health care delivery in India. In September 2019, Federal Health Minister Jens Spahn declared that he would adhere further to the reimbursability of homeopathy by the statutory health insurance funds.
Fourrts, Allen Healthcare Co. Ltd; Hahnemann Laboratories, Inc; Boiron, Homeocan Inc; Hyland's, Inc. Nelson Pharmacies Limited, Weleda UK , Biologische Heilmittel Heel GmbH; Ainsworths (London) Limited DHU-Arzneimittel GmbH & Co. KG; Dr Reckeweg & Co GmbH, Similasan Corp; PEKANA Naturheilmittel GmbH are among the leading companies operating in the homeopathy market.
Various organic and inorganic strategies are adopted by companies operating in the homeopathy market. Organic strategies mainly include product launches and product approvals. Further, acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players operating in the homeopathy market are listed below.
- In July 2022, Boiron granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.
- In Dec 2020, Fourrts launched FILOFLUE, (Homeopathic Preparation) for treatment of Flu like symptoms. It helps in relieving cough and throat irritation and helps in strengthening the immune system.
Contact Us
Contact Us: The Insight Partners
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
Related Industry Updates
Drugmaker Sanofi to raise over $11 billion by selling its U.S. partner Regeneron shares
May 27, 2020
Prostate Cancer Therapeutics Market is expected to grow US$ 28,425.27 million by 2030
Dec 12, 2023
TOWA PHARMACEUTICAL CO., LTD. reaches an agreement with ESTEVE to acquire ESTEVE's generic division, Pensa Investments
Dec 24, 2019
Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts
May 26, 2020
Asia Pacific Companion Animal Diagnostics Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027| Fujifilm Corporation, Skyla Corporation, Virbac
Jan 15, 2021
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020
Takeda’s $1.7B AI Drug Discovery Deal with Iambic Signals Shift
Feb 10, 2026